66 related articles for article (PubMed ID: 16557598)
1. Bystander effects are induced by CENU treatment and associated with altered protein secretory activity of treated tumor cells: a relay for chemotherapy?
Demidem A; Morvan D; Madelmont JC
Int J Cancer; 2006 Sep; 119(5):992-1004. PubMed ID: 16557598
[TBL] [Abstract][Full Text] [Related]
2. CENU treatment induced bystander effects which are effective on parental and non-parental tumors and have a phospholipid metabolism proton NMR spectroscopy signature.
Merle P; Morvan D; Madelmont JC; Caillaud D; Demidem A
Int J Oncol; 2006 Sep; 29(3):637-42. PubMed ID: 16865279
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-induced bystander effect in response to several chloroethylnitrosoureas: an origin independent of DNA damage?
Merle P; Morvan D; Caillaud D; Demidem A
Anticancer Res; 2008; 28(1A):21-7. PubMed ID: 18383820
[TBL] [Abstract][Full Text] [Related]
4. Combined methionine deprivation and chloroethylnitrosourea have time-dependent therapeutic synergy on melanoma tumors that NMR spectroscopy-based metabolomics explains by methionine and phospholipid metabolism reprogramming.
Guénin S; Morvan D; Thivat E; Stepien G; Demidem A
Nutr Cancer; 2009; 61(4):518-29. PubMed ID: 19838924
[TBL] [Abstract][Full Text] [Related]
5. Metabolomics by proton nuclear magnetic resonance spectroscopy of the response to chloroethylnitrosourea reveals drug efficacy and tumor adaptive metabolic pathways.
Morvan D; Demidem A
Cancer Res; 2007 Mar; 67(5):2150-9. PubMed ID: 17332345
[TBL] [Abstract][Full Text] [Related]
6. N-(2-chloroethyl)-N-nitrosourea tethered to lexitropsin induces minor groove lesions at the p53 cDNA that are more cytotoxic than mutagenic.
Inga A; Chen FX; Monti P; Aprile A; Campomenosi P; Menichini P; Ottaggio L; Viaggi S; Abbondandolo A; Gold B; Fronza G
Cancer Res; 1999 Feb; 59(3):689-95. PubMed ID: 9973219
[TBL] [Abstract][Full Text] [Related]
7. Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma.
Nakajima M; Hayashi K; Egi Y; Katayama K; Amano Y; Uehata M; Ohtsuki M; Fujii A; Oshita K; Kataoka H; Chiba K; Goto N; Kondo T
Cancer Chemother Pharmacol; 2003 Oct; 52(4):319-24. PubMed ID: 12783205
[TBL] [Abstract][Full Text] [Related]
8. PP2A activity is controlled by methylation and regulates oncoprotein expression in melanoma cells: a mechanism which participates in growth inhibition induced by chloroethylnitrosourea treatment.
Guénin S; Schwartz L; Morvan D; Steyaert JM; Poignet A; Madelmont JC; Demidem A
Int J Oncol; 2008 Jan; 32(1):49-57. PubMed ID: 18097542
[TBL] [Abstract][Full Text] [Related]
9. Metabolomics and transcriptomics demonstrate severe oxidative stress in both localized chemotherapy-treated and bystander tumors.
Morvan D; Demidem A
Biochim Biophys Acta; 2014 Mar; 1840(3):1092-104. PubMed ID: 24296419
[TBL] [Abstract][Full Text] [Related]
10. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
11. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness.
Carreira S; Goodall J; Denat L; Rodriguez M; Nuciforo P; Hoek KS; Testori A; Larue L; Goding CR
Genes Dev; 2006 Dec; 20(24):3426-39. PubMed ID: 17182868
[TBL] [Abstract][Full Text] [Related]
12. FGF-2 induced reorganization and disruption of actin cytoskeleton through PI 3-kinase, Rho, and Cdc42 in corneal endothelial cells.
Lee HT; Kay EP
Mol Vis; 2003 Dec; 9():624-34. PubMed ID: 14685150
[TBL] [Abstract][Full Text] [Related]
13. A model of phospholipid biosynthesis in tumor in response to an anticancer agent in vivo.
Behzadi M; Demidem A; Morvan D; Schwartz L; Stepien G; Steyaert JM
J Integr Bioinform; 2010 Mar; 7(3):. PubMed ID: 20375456
[TBL] [Abstract][Full Text] [Related]
14. Cystemustine induces redifferentiation of primary tumors and confers protection against secondary tumor growth in a melanoma murine model.
Demidem A; Morvan D; Papon J; De Latour M; Madelmont JC
Cancer Res; 2001 Mar; 61(5):2294-300. PubMed ID: 11280801
[TBL] [Abstract][Full Text] [Related]
15. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
16. Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma.
Shiose S; Sakamoto T; Yoshikawa H; Hata Y; Kawano Y; Ishibashi T; Inomata H; Takayama K; Ueno H
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2395-403. PubMed ID: 10937546
[TBL] [Abstract][Full Text] [Related]
17. A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo.
Rastelli L; Valentino ML; Minderman MC; Landin J; Malyankar UM; Lescoe MK; Kitson R; Brunson K; Souan L; Forenza S; Goldfarb RH; Rabbani SA
Int J Oncol; 2011 Aug; 39(2):401-8. PubMed ID: 21567086
[TBL] [Abstract][Full Text] [Related]
18. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.
López-Fauqued M; Gil R; Grueso J; Hernandez-Losa J; Pujol A; Moliné T; Recio JA
Int J Cancer; 2010 Apr; 126(7):1549-61. PubMed ID: 19810100
[TBL] [Abstract][Full Text] [Related]
19. DNA crosslinking, sister chromatid exchange and cytotoxicity of N-2-chloroethylnitrosoureas tethered to minor groove binding peptides.
Chen FX; Zhang Y; Church KM; Bodell WJ; Gold B
Carcinogenesis; 1993 May; 14(5):935-40. PubMed ID: 8504487
[TBL] [Abstract][Full Text] [Related]
20. The effect of topiramate on tumor-related angiogenesis and on the serum proteome of mice bearing Lewis lung carcinoma.
Ma B; Pan Y; Song Q; Tie L; Zhang Y; Xiao Y; Zhang J; Han J; Xu Y; Xiang Y; Yu HM; Li XJ
Eur J Pharmacol; 2011 Aug; 663(1-3):9-16. PubMed ID: 21596032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
